The success of organ transplantation owes much to improvementsin the immunosuppressive regimens that prevent or suppress allograftrejection. Nevertheless, the potent immunosuppressive drugsthat are now in general use increase susceptibility to infectionand cancer and can also have adverse effects not directly relatedto immunosuppression.
Conventional immunosuppressive agents affect not only immunecells but also other cells. Glucocorticoids, for example, cancause a myriad of side effects,1 but these harmful actions areoften minimized by combining glucocorticoids with other immunosuppressivemedications. In use since the early days of transplantation,small-molecule immunosuppressive drugs act by targeting DNAor proteins . . . [Full Text of this Article]
This article has been cited by other articles:
Socie, G., Blazar, B. R.
(2009). Acute graft-versus-host disease: from the bench to the bedside. Blood
114: 4327-4336
[Abstract][Full Text]
Tattevin, P., Le Tulzo, Y., Schwartz, S., Ruhnke, M., Ribaud, P., Corey, L., Driscoll, T., Cornely, O. A., Schuler, U., Lutsar, I., Troke, P., Thiel, E.
(2006). Improved outcome in central nervous system aspergillosis. Blood
107: 3410-3412
[Full Text]
Dharnidharka, V. R., Vincenti, F.
(2005). Costimulation Blockade with Belatacept in Renal Transplantation.. NEJM
353: 2085-2086
[Full Text]